Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and expressed gratitude for his contributions, while the company plans to appoint a successor soon. This change reflects Fontoura's career advancement and may impact Lakefront's board dynamics going forward.
The global influenza vaccine market, valued at $8.96 billion in 2024, is projected to reach $13.32 billion by 2030 with a 7% annual growth rate. Growth is fueled by rising public health awareness, an expanding elderly population, government immunizat...
Novavax reported $57 million in revenue for Q2 2026, down 76% from last year due to milestone timing but saw a 76% rise in product sales. The company is progressing with its Sanofi partnership, including advanced talks on a Phase 3 COVID-19-Influenza...
Sanofi is rated a Buy with an estimated 33.5% upside to a fair value of €99.5 per share, driven mainly by the strong growth prospects of its key drug Dupixent, which targets €25 billion in sales by 2030. However, Dupixent faces risks from biosimilar ...
Nurix Therapeutics received a $10 million milestone payment from Sanofi after Sanofi initiated a Phase 1 clinical trial of SAR448272/NX-3911, an oral STAT6 degrader targeting type 2 inflammatory diseases like atopic dermatitis and asthma. This milest...
The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as six weeks old to protect against invasive meningococcal disease caused by serogroups A, C, W, and Y. Previously approved for those aged 12 months and older...
